Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters










Database
Language
Publication year range
1.
PLoS One ; 8(2): e57802, 2013.
Article in English | MEDLINE | ID: mdl-23460910

ABSTRACT

BACKGROUND: Chemerin is a specific chemoattractant for macrophages and dendritic cells (DC). In addition, it can rapidly stimulate macrophage adhesion to extracellular matrix proteins and adhesion molecules and is able to activate fibroblast-like synoviocytes (FLS), suggesting a role in the pathogenesis of rheumatoid arthritis (RA). Chemerin is also an adipocytokine that has been related to the inflammatory state of endothelial cells and as such could be involved in the changes in endothelial cells in RA and perhaps increased cardiovascular morbidity. We investigated whether anti-Tumor Necrosis Factor (TNF) treatment affects chemerin levels. MATERIALS AND METHODS: 49 patients with active RA (disease activity score evaluated in 28 joints (DAS28) ≥3.2) were started on adalimumab therapy. Blood was drawn from patients while fasting at baseline and 16 weeks after initiation of treatment. Chemerin serum levels were measured by ELISA and related to disease activity, mediators of inflammation and known risk factors for cardiovascular disease. RESULTS: Adalimumab therapy reduced chemerin serum levels, which was correlated with the reduction in DAS28 (r = 0.37, p = 0.009). In addition, the decrease in chemerin serum levels after anti-TNF treatment was associated with the decrease in serum levels of IL-6 (r = 0.39, p = 0.033) and macrophage migration inhibitory factor (MIF) (r = 0.31, p = 0.049). Baseline chemerin serum levels were not related to traditional risk factors for atherosclerosis, except perhaps for smoking (p = 0.07). CONCLUSIONS: This exploratory study shows that adalimumab therapy lowers chemerin levels, which is associated with the reduction in disease activity parameters, and inflammatory mediators IL-6 and MIF. This suggests a possible involvement of chemerin in the migration/retention of macrophages in the synovium. TRIAL REGISTRATION NEDERLANDS TRIAL REGISTER: NTR 857.


Subject(s)
Antibodies, Monoclonal, Humanized/therapeutic use , Arthritis, Rheumatoid/blood , Arthritis, Rheumatoid/drug therapy , Chemokines/blood , Inflammation/blood , Inflammation/drug therapy , Tumor Necrosis Factor-alpha/antagonists & inhibitors , Adalimumab , Antibodies, Monoclonal, Humanized/pharmacology , Atherosclerosis/blood , Atherosclerosis/pathology , Female , Humans , Intercellular Signaling Peptides and Proteins , Interleukin-6/blood , Macrophage Migration-Inhibitory Factors/blood , Male , Middle Aged , Risk Factors , Smoking/blood , Tumor Necrosis Factor-alpha/metabolism
2.
Disabil Rehabil ; 33(25-26): 2587-95, 2011.
Article in English | MEDLINE | ID: mdl-21671833

ABSTRACT

PURPOSE: To investigate the experiences and needs with respect to work participation of employees with rheumatoid arthritis (RA) treated with anti-tumour necrosis factor (TNF) therapy. METHOD: Face-to-face interviews in 14 employees with RA on anti-TNF therapy focused on experiences, offered support and needs with respect to work participation. RESULTS: Experiences regarding work participation varied and ranged from fatigue at work, having no job control, not being understood by the work environment or difficulty dealing with emotions as a result of interaction within the work environment. Support by health care professionals for work participation was considered important, especially concerning social or psychological issues. Advice in becoming aware of one's changes in abilities was highly appreciated, as was the availability of professional advice in times of an urgent work issue due to RA. Employees mentioned an increase in social support at work and job control as important facilitating factors for work participation. CONCLUSION: Although patients with RA report improvement in their work functioning after starting anti-TNF therapy, employees continue facing challenges in working life due to RA. For support concerning work participation, it is recommended that health care professionals are more aware of work-related problems in patients with RA treated with anti-TNF therapy.


Subject(s)
Arthritis, Rheumatoid/drug therapy , Arthritis, Rheumatoid/rehabilitation , Employment , Tumor Necrosis Factor-alpha/antagonists & inhibitors , Adalimumab , Adult , Antibodies, Monoclonal, Humanized/therapeutic use , Arthritis, Rheumatoid/psychology , Employment/psychology , Employment/statistics & numerical data , Female , Humans , Male , Middle Aged , Social Support , Young Adult
3.
J Occup Environ Med ; 52(6): 618-21, 2010 Jun.
Article in English | MEDLINE | ID: mdl-20523240

ABSTRACT

OBJECTIVE: To assess the effect of 12-month treatment with adalimumab on work ability, quality of life, and fatigue in patients with active rheumatoid arthritis (RA). METHODS: One hundred twenty-six patients with active RA started treatment with adalimumab. Primary outcome measurements were work ability, assessed by the first item of the Work Ability Index, quality of life, assessed by the Rheumatoid Arthritis Quality of Life (RAQoL) instrument, and fatigue, assessed by the Checklist Individual Strength and the Need for Recovery after work Scale. RESULTS: All primary outcome measurements showed a significant improvement. The largest improvement for all outcome measurements was gained in the first 6 months of treatment and was sustained over the following 6 months. CONCLUSION: Adalimumab improves patient reported outcomes in addition to improving disease activity in established RA.


Subject(s)
Antibodies, Monoclonal/therapeutic use , Antirheumatic Agents/therapeutic use , Arthritis, Rheumatoid/drug therapy , Efficiency , Fatigue/drug therapy , Tumor Necrosis Factor Inhibitors , Adalimumab , Adult , Antibodies, Monoclonal, Humanized , Arthritis, Rheumatoid/physiopathology , Cohort Studies , Disability Evaluation , Female , Humans , Male , Methotrexate/therapeutic use , Middle Aged , Prospective Studies , Quality of Life
SELECTION OF CITATIONS
SEARCH DETAIL
...